It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
-
The Role of Scientific Advisers in the English Patents Court
-
Trying to Make Sense of the Oracle of G 2/21: T 116/18 vs. T 681/21
-
Patent case: NanoString Technologies vs. 10x Genomics and President and Fellows of Harvard College, UPC
-
Patent case: Judgment no. 141/2023 dated 5 December 2023, Spain
Random Articles:
-
‘Pro-patent bias is a serious risk at the Unified Patent Court’
-
Danish Court finds that the Danish Patent and Trademark Office is not obligated to consider ex officio the risk of double patenting for utility models
-
SPC cases are back and there are more to come: will the CJEU definitively heal the Medeva wounds on 12 march, or will it rub salt into them?
-
‘Restricting competencies Milan as third seat central division Unified Patent Court is unacceptable’
-
Staying UK Proceedings Pending EPO Oppositions – Commercial Common Sense Prevails
-
USA: Cutsforth, Inc. v. MotivePower, Inc, United States Court of Appeals, Federal Circuit, No. 2015-1316, 22 January 2016
-
Patenting antibody-related inventions in Brazil
-
Monsanto v. Nuziveedu: A Missed Opportunity by the Supreme Court?
-
Patent case: Driessen v. Best Buy Co., Inc., USA
-
EPO, Infringement, Injunction, Patents, Pharma, Pharmaceutical patent, Second Medical Use, United Kingdom
A wake-up call for patentees?